Other substances

Berzosertib

A protein kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Berzosertib is a sulphonamide (ChEBI) protein kinase inhibitor targeting ATR (ataxia telangiectasia and Rad3-related protein) (Garcia Jr. et al., 2021). ATR is a key DNA damage repair signalling factor. Berzosertib is clinically trialled in oncotherapy (Gorecki et al., 2020). It has been shown to inhibit SARS-CoV-2 infection at a post-entry stage in vitro (Garcia Jr. et al., 2021).

Berzosertib on DrugBank
Berzosertib on PubChem
Berzosertib on Wikipedia

Synonyms

VE-822; VX-970; M6620

 

Structure image - Berzosertib

CC(C)S(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C3=CC(=NO3)C4=CC=C(C=C4)CNC)N

Supporting references

Link Tested on Impact factor Notes Publication date
Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication
Preprint Screening 		VERO E6 cell cultures Jun/25/2020
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
Small molecule In vitro Mechanism 		Vero E6 cells; Calu-3 cells; HEK293-ACE2 cells; HeLa-ACE2 cells; A549-ACE2 cells; human-induced pluripotent stem-cell-derived cardiomyocyte; SARS-CoV-2 isolate USA-WA1/2020 8.11

The drug inhibited SARS-CoV-2 infection in various cell lines (including human-induced pluripotent stem-cell-derived cardiomyocytes) without significant cytotoxicity. It was shown to act at a post-entry stage of infection.

 Mar/17/2021
Export (.csv)